Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 25Uveal Melanoma 5Neoplasms 5Skin Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Prostatic Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Eye Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenoma, Islet Cell 2Urologic Neoplasms 1Stomach Neoplasms 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms by Site 1Myelodysplastic Syndromes 1Muscle Neoplasms 1Multiple Myeloma 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Rituximab 313Cyclophosphamide 286fludarabine phosphate 213fludarabine 140ibrutinib 121Peripheral Blood Stem Cell Transplantation 116venetoclax 108Mycophenolic Acid 102obinutuzumab 88Lenalidomide 88Bendamustine Hydrochloride 87Whole-Body Irradiation 85Filgrastim 84Tacrolimus 78Cyclosporine 78Busulfan 70Melphalan 65Radiotherapy 63Antilymphocyte Serum 61Alemtuzumab 58Etoposide 56acalabrutinib 54Methotrexate 49ofatumumab 46idelalisib 38Cytarabine 33Chlorambucil 33zanubrutinib 31sargramostim 30Specimen Handling 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × montanide ISA 51 × Clear all
NCT03939234 2022-02-21

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Herlev Hospital

Phase 2 Completed
19 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡